More recently, the non-steroidal mineralocorticoid receptor antagonist (MRA) finerenone has been incorporated into treatment guidelines by certain societies [5, 6] following evidence supporting its benefit in certain subpopulations, particularly patients with diabetic kidney disease (DKD) [7, 8]. Here, NR3C2 is linked to diabetic kidney disease.